Accropeutics’ Oral Selective TYK2/JAK1 Inhibitor Performs Well in Phase 2 Study of Moderate-to-Severe Plaque PsO
Accropeutics’ oral, selective tyrosine kinase 2 (TYK2) inhibitor /Janus kinase (JAK)1 Inhibitor hit the primary and key secondary endpoints in a Phase 2 clinical trial in moderate-to-severe plaque psoriasis.